A large chunk of the fund’s assets (about 25%) sits in biotech and pharma stocks, including its biggest three holdings: Eli Lilly LLY, Biogen BIIB, and Amgen AMGN. Those industries amount to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果